Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.

Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R; Pasireotide B2305 Study Group.

Pituitary. 2015 Oct;18(5):604-12. doi: 10.1007/s11102-014-0618-1.

2.

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.

Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM; Pasireotide B2305 Study Group.

Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17. doi: 10.1111/cen.12431. Epub 2014 Mar 27.

PMID:
24533697
3.

High variability in baseline urinary free cortisol values in patients with Cushing's disease.

Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado LR, Colao A, Biller BM; Pasireotide B2305 Study Group.

Clin Endocrinol (Oxf). 2014 Feb;80(2):261-9. doi: 10.1111/cen.12259. Epub 2013 Jul 15.

4.

A 12-month phase 3 study of pasireotide in Cushing's disease.

Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM; Pasireotide B2305 Study Group.

N Engl J Med. 2012 Mar 8;366(10):914-24. doi: 10.1056/NEJMoa1105743. Erratum in: N Engl J Med. 2012 Aug 23;367(8):780.

5.

"ECG variability contour" method reveals amplitude changes in both ischemic patients and normal subjects during Dipyridamole stress: a preliminary report.

Dori G, Gershinsky M, Ben-Haim S, Lewis BS, Bitterman H.

Med Biol Eng Comput. 2011 Nov;49(11):1311-20. doi: 10.1007/s11517-011-0835-y. Epub 2011 Oct 4.

PMID:
21969223
6.

Total versus hemithyroidectomy for microscopic papillary thyroid cancer.

Gershinsky M, Barnett-Griness O, Stein N, Hirsch D, Tzvetov G, Bardicef O, Pauker J, Grozinsky-Glasberg S, Ish-Shalom S, Slutski I, Shimon I, Benbassat C.

J Endocrinol Invest. 2012 May;35(5):464-8. doi: 10.3275/7963. Epub 2011 Sep 27.

PMID:
21952495
7.

Changes in the initial slope of the QRS in ischemic patients and normal subjects undergoing scintigraphy with dipyridamole.

Dori G, Gershinsky M, Ben-Haim S, Lewis BS, Bitterman H.

Comput Biol Med. 2010 Nov-Dec;40(11-12):869-75. doi: 10.1016/j.compbiomed.2010.09.007. Epub 2010 Oct 15.

PMID:
20950799
8.

Efficacy of long-term lanreotide treatment in patients with acromegaly.

Toledano Y, Rot L, Greenman Y, Orlovsky S, Pauker Y, Olchovsky D, Eliash A, Bardicef O, Makhoul O, Tsvetov G, Gershinsky M, Cohen-Ouaqnine O, Ness-Abramof R, Adnan Z, Ilany J, Guttmann H, Sapir M, Benbassat C, Shimon I.

Pituitary. 2009;12(4):285-93. doi: 10.1007/s11102-009-0172-4.

PMID:
19266287
9.

Imaging of oncogenic osteomalacia.

Gershinsky M, Croitoru S, Dickstein G, Bardicef O, Gelman R, Barmeir E.

Isr Med Assoc J. 2007 Jul;9(7):566-7. No abstract available.

Supplemental Content

Loading ...
Support Center